Health technology assessment of tests for SARSCoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations.

Autor: Elvidge, Jamie, Summerfield, Ashley, Knies, Saskia, Németh, Bertalan, Kaló, Zoltán, Goettsch, Wim, Dawoud, Dalia M.
Zdroj: International Journal of Technology Assessment in Health Care; 2023, Vol. 39 Issue 1, p1-6, 6p, 2 Diagrams
Abstrakt: Objectives: To develop best-practice guidance for health technology assessment (HTA) agencies when appraising diagnostic tests for SARS-CoV-2 and treatments for COVID-19. Methods: We used a policy sandbox approach to develop best-practice guidance for HTA agencies to approach known challenges associated with assessing tests and treatments for COVID-19. The guidance was developed by a multi-stakeholder workshop of twenty-one participants representing HTA agencies, clinical and patient experts, academia, industry, and a payer, from across Europe and North America. The workshop was supported by extensive background work to identify the key challenges, including: targeted reviews of existing COVIDrelated methods guidance for assessing interventions and clinical guidelines, engagement with clinical experts, a survey and workshop of HTA agencies, a systematic review of published economic evaluations, and a workshop of health economic modelers. Results: We suggest HTA agencies should consider using other types of evidence (e.g., real world) where high-quality randomized controlled trials may be lacking and healthcare systems would value timely HTA outputs. A “living” HTA approach may be useful, given the context of an evolving disease, scientific understanding and evidence base, allowing for decisions to be efficiently revisited in response to new information; particularly, if supported by a common “disease model” for COVID-19. Innovative ways of engaging with the public and clinicians, and early engagement with regulators and payers, are recommended. Conclusions: HTA agencies should consider the elements of this guidance that are most suited to their existing processes to enable them to assess the effectiveness and value of interventions for COVID-19. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index